Type to search

Developing a Psilocybin Drug Company; Interview with Judy Blumstock, Founder and CEO of Diamond Therapeutics


As one of Canada’s top health science executives, Judy Blumstock has over 25 years of venture capital and private equity experience in life sciences and biotechnology. She spent more than ten years as the executive director of corporate development at Toronto Innovation Acceleration Partners (TIAP), formerly known as MaRS Innovation.

Before this, Ms. Blumstock was a principal with Genesys Capital, one of the largest Canadian-based venture-capital firms focused exclusively on the life sciences industry and was a partner with RBC Capital Partners life sciences fund. Ms. Blumstock was also the director of biological and pharmaceutical research at Drug Royalty Corporation (now DRI Capital Inc.), which provides financial solutions in exchange for royalties to health-related organizations worldwide.

In 2018 she founded Diamond Therapeutics and is the CEO. We had the chance to interview Judy at the recent Lift&Co psychedelics conference in Toronto, and learn more about developing a prescription medicine with the psilocybin compound specifically for micro-dosing, and why this is important.

Q. What problem is Diamond Therapeutics trying to solve?

This content is exclusive to Alpha Woman Members

To view the full article, please subscribe.

Already a subscriber? Sign In

Leslie Andrachuk

As a bilingual pioneer in global digital publishing and marketing, Leslie is happiest when creating new things and inspiring her teams. She is passionate about changing biases that hold women back from realizing their true power and is grateful that at this point in her career she has the skills to make real change.

  • 1

You Might also Like

Leave a Comment

Your email address will not be published. Required fields are marked *